Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BY-NCInfection & chemotherapy

Diagnostic and Therapeutic Perspectives on Persistent HIV-1 Low-Level Viremia.

  • Chang Kyung Kang1,2
  • Jonathan Z Li3
  1. 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  2. 2Deparment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. [email protected].
  3. 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. [email protected].
Read full textPDFDOICite

Abstract

While modern antiretroviral therapy achieves high rates of virologic suppression, persistent low-level viremia (pLLV) remains a common clinical scenario that poses distinct diagnostic and therapeutic dilemmas. This review proposes a systematic diagnostic approach to pLLV, beginning with a thorough evaluation of adherence, potential drug-drug interactions, dietary considerations, and resistance profiles. Such a structured assessment is essential to differentiate diverse pathophysiological conditions, particularly in distinguishing active replication-driven failure from reservoir-derived non-suppressible viremia (NSV). Management strategies are tailored to these findings: extrinsic factors, such as suboptimal adherence or pharmacological barriers, are managed through targeted optimization, while intrinsic resistance necessitates switching to fully active regimen. In contrast, NSV is a reservoir-driven process that does not necessitate ART regimen intensification or modification. We also examine key considerations for recently introduced long-acting injectables in the context of pLLV. Furthermore, we address sexual transmission risks, emphasizing that while the risk remains extremely low within the pLLV range, clinical vigilance is crucial given the risks of virologic failure. Successful pLLV management therefore relies on a tailored approach that balances proactive clinical intervention with judicious observation, ensuring virologic control and patient quality of life.

Related

  1. Therapeutic cancer vaccines: development, challenges, and future perspectives
    Di Di, Luan-feng Li, Tian-yang He +5
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text1 citedImmunologyPMC
  2. Role of PI3K/Akt/mTOR signaling in the therapeutic effects of Fuzheng Lishi Huayu Decoction on persistent Chlamydia trachomatis infection
    Zhihua Song, Siyun Zhou, Xuelian Tian +4
    Journal of traditional and complementary medicinePeer-reviewedCC BY-NC-NDFull textMicrobiologyEurope PMCPMC
  3. Netherton syndrome presenting with generalized erythroderma in a preterm neonate: Diagnostic and therapeutic challenges.
    Zahra Khodabakhshian, Naser Tayyebi Meibodi, Ahmad Reza Taheri
    JAAD case reportsPeer-reviewedCC BYFull textCell biologyEurope PMC
  4. Beyond minutes played: Rotation architecture as a persistent club-level signature in elite basketball
    Jaime Sampaio, Miguel Ángel Gómez, Francesco Cuzzolin +1
    PLOS OnePeer-reviewedCC BY 4.0Full textZoology & animal behaviourMaterials & polymersPLOSPMC
  5. Fibrotic Remodeling in Retinal Vascular Diseases: Cellular Origins, Molecular Mechanisms, and Therapeutic Perspectives.
    Jia Yu Ning, Brian Wang, Miyuki Ishida Yamamoto +1
    CellsPeer-reviewedCC BYFull textCell biologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kang2026diagnostic,
  title = {{Diagnostic and Therapeutic Perspectives on Persistent HIV-1 Low-Level Viremia.}},
  author = {Chang Kyung Kang and Jonathan Z Li},
  journal = {Infection \& chemotherapy},
  year = {2026},
  month = sep,
  doi = {10.3947/ic.2026.0076},
  url = {https://europepmc.org/article/MED/42847624},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Diagnostic and Therapeutic Perspectives on Persistent HIV-1 Low-Level Viremia.
AU  - Chang Kyung Kang
AU  - Jonathan Z Li
PY  - 2026
DA  - 2026/09/01
JO  - Infection & chemotherapy
DO  - 10.3947/ic.2026.0076
UR  - https://europepmc.org/article/MED/42847624
AB  - While modern antiretroviral therapy achieves high rates of virologic suppression, persistent low-level viremia (pLLV) remains a common clinical scenario that poses distinct diagnostic and therapeutic dilemmas. This review proposes a systematic diagnostic approach to pLLV, beginning with a thorough evaluation of adherence, potential drug-drug interactions, dietary considerations, and resistance profiles. Such a structured assessment is essential to differentiate diverse pathophysiological conditions, particularly in distinguishing active replication-driven failure from reservoir-derived non-suppressible viremia (NSV). Management strategies are tailored to these findings: extrinsic factors, such as suboptimal adherence or pharmacological barriers, are managed through targeted optimization, while intrinsic resistance necessitates switching to fully active regimen. In contrast, NSV is a reservoir-driven process that does not necessitate ART regimen intensification or modification. We also examine key considerations for recently introduced long-acting injectables in the context of pLLV. Furthermore, we address sexual transmission risks, emphasizing that while the risk remains extremely low within the pLLV range, clinical vigilance is crucial given the risks of virologic failure. Successful pLLV management therefore relies on a tailored approach that balances proactive clinical intervention with judicious observation, ensuring virologic control and patient quality of life.
SN  - 2093-2340
SN  - 2092-6448
ER  -